SHR-8068

SHR-8068 is an investigational agent whose form is not stated in the registry developed by Suzhou Suncadia Biopharmaceuticals and Shanghai Hengrui Pharmaceutical. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: SHR-8068: injection, 50mg（10mL）/ bottle, intravenous drip. It is the investigational product in 10 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT07229625 (A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC)), in biliary tract cancer, non-small-cell lung cancer, cervical cancer, gastric & gastro-oesophageal junction cancer and bladder & urothelial cancer. The largest, NCT06703177, plans to enrol 876 participants with primary completion expected 2026-01-01. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.